Literature DB >> 10480511

Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women.

A Pascot1, S Lemieux, I Lemieux, D Prud'homme, A Tremblay, C Bouchard, A Nadeau, C Couillard, A Tchernof, J Bergeron, J P Després.   

Abstract

OBJECTIVE: Age-related differences in body fat and, more specifically, in the accumulation of abdominal visceral adipose tissue (AT) were examined as potential covariates of the age-related difference in the metabolic profile predictive of cardiovascular disease (CVD) risk observed in young, as compared with middle-aged, premenopausal women. RESEARCH DESIGN AND METHODS: Body composition, AT distribution, plasma lipoprotein-lipid levels, glucose tolerance, and plasma insulin concentrations were assessed in a sample of 122 young women (27.4+/-7.5 years, mean +/- SD) and compared with a sample of 52 middle-aged premenopausal women (49.5+/-5.3 years) who still had a normal menstrual cycle.
RESULTS: Middle-aged women were characterized by elevated levels of total abdominal and visceral AT and greater body fat mass and waist circumference, as well as by higher plasma levels of total cholesterol, LDL cholesterol, apolipoprotein (apo)B, and LDL-apoB compared with younger women. Furthermore, middle-aged women showed a greater glycemic response to a 75-g oral glucose load than young women (P < 0.01). In both young and middle-aged subjects, visceral AT accumulation was significantly correlated with plasma triglyceride, apoB, and LDL-apoB levels and with the cholesterol/HDL cholesterol ratio, as well as with plasma glucose, insulin, and C-peptide levels measured in the fasting state and after the oral glucose load, and negatively correlated with HDL cholesterol levels (-0.41 < or = r < or = 0.65, P < 0.05). When variables were adjusted for levels of visceral AT and fat mass, age-related differences that were initially found in plasma apoB and LDL-apoB levels, as well as in fasting glycemia and glucose tolerance, were eliminated.
CONCLUSIONS: Results of the present study suggest that even before the onset of menopause there is an age-related deterioration in the metabolic risk profile and an increase in visceral AT deposition in middle-aged women compared with young control subjects. Furthermore, our results provide support for the notion that the age-related increase in visceral AT accumulation is a significant factor involved in the deterioration of the CVD risk profile noted in premenopausal women with age.

Entities:  

Mesh:

Year:  1999        PMID: 10480511     DOI: 10.2337/diacare.22.9.1471

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  48 in total

1.  Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue.

Authors:  Carey N Lumeng; Jianhua Liu; Lynn Geletka; Colin Delaney; Jennifer Delproposto; Anjali Desai; Kelsie Oatmen; Gabriel Martinez-Santibanez; Annabelle Julius; Sanjay Garg; Raymond L Yung
Journal:  J Immunol       Date:  2011-11-09       Impact factor: 5.422

2.  Significant associations of age, menopausal status and lifestyle factors with visceral adiposity in African-American and European-American women.

Authors:  Ellen W Demerath; Nikki L Rogers; Derek Reed; Miryoung Lee; Audrey C Choh; Roger M Siervogel; Wm Cameron Chumlea; Bradford Towne; Stefan A Czerwinski
Journal:  Ann Hum Biol       Date:  2010-12-22       Impact factor: 1.533

3.  Association of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study.

Authors:  Meredith C Foster; Shih-Jen Hwang; Joseph M Massaro; Udo Hoffmann; Ian H DeBoer; Sander J Robins; Ramachandran S Vasan; Caroline S Fox
Journal:  Obesity (Silver Spring)       Date:  2010-12-23       Impact factor: 5.002

4.  Childbearing may increase visceral adipose tissue independent of overall increase in body fat.

Authors:  Erica P Gunderson; Barbara Sternfeld; Melissa F Wellons; Rachel A Whitmer; Vicky Chiang; Charles P Quesenberry; Cora E Lewis; Stephen Sidney
Journal:  Obesity (Silver Spring)       Date:  2008-03-06       Impact factor: 5.002

5.  Body composition, fitness, and metabolic health during strength and endurance training and their combination in middle-aged and older women.

Authors:  Elina Sillanpää; David E Laaksonen; Arja Häkkinen; Laura Karavirta; Benjamin Jensen; William J Kraemer; Kai Nyman; Keijo Häkkinen
Journal:  Eur J Appl Physiol       Date:  2009-03-06       Impact factor: 3.078

6.  Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease.

Authors:  Jaividhya Dasarathy; Pranav Periyalwar; Sanath Allampati; Vikram Bhinder; Carol Hawkins; Patricia Brandt; Amer Khiyami; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Liver Int       Date:  2013-10-01       Impact factor: 5.828

7.  Associations between gestational weight gain and BMI, abdominal adiposity, and traditional measures of cardiometabolic risk in mothers 8 y postpartum.

Authors:  Candace K McClure; Janet M Catov; Roberta Ness; Lisa M Bodnar
Journal:  Am J Clin Nutr       Date:  2013-09-18       Impact factor: 7.045

8.  Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk.

Authors:  Marco C Amato; Carla Giordano; Massimo Galia; Angela Criscimanna; Salvatore Vitabile; Massimo Midiri; Aldo Galluzzo
Journal:  Diabetes Care       Date:  2010-01-12       Impact factor: 17.152

Review 9.  Changes in adipose tissue macrophages and T cells during aging.

Authors:  Sanjay K Garg; Colin Delaney; Hang Shi; Raymond Yung
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

10.  Association of lifestyle factors with abdominal subcutaneous and visceral adiposity: the Framingham Heart Study.

Authors:  Esther A Molenaar; Joseph M Massaro; Paul F Jacques; Karla M Pou; R Curtis Ellison; Udo Hoffmann; Karol Pencina; Steven D Shadwick; Ramachandran S Vasan; Christopher J O'Donnell; Caroline S Fox
Journal:  Diabetes Care       Date:  2008-12-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.